Navigation Links
Bradmer Medical Isotope Supply For Phase III Trial Secure
Date:12/10/2007

TSX: BMR

TORONTO, Dec. 10 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that the start of Company's planned Phase III trial of Neuradiab, a murine monoclonal antibody radiolabeled with Iodine-131 (I-131), is unaffected by the recent shortage of medical isotopes from a nuclear facility in Chalk River, Ontario. Bradmer procures its I-131 material used to prepare Neuradiab from commercial sources outside North America as well as a back up facility that are not affected by the recent events at Chalk River.

"The medical isotope production issues have received a significant amount of attention recently, and we felt it would be appropriate to update our shareholders and stakeholders on the situation as it relates to Bradmer. We made decisions earlier this year that ensured both the clinical and commercial supplies of the radioisotope for our product candidate, Neurabiab," said Alan M. Ezrin, Ph.D., President and Chief Executive Officer of Bradmer. "Our formulation work, completed earlier this year, indicated that the I-131 we use yielded consistent and reproducible product which we have validated for clinical use at a commercial scale for the upcoming Phase III trial. In addition, we have made contingency plans to ensure we can modify our protocol accordingly to conduct the imaging flow studies that are required in our Phase III trial if the shortage of Technetium as a diagnostic agent continues due to the current events."

Bradmer has invested the better part of the past year securing and validating the commercial production of Neuradiab. The Company has completed the final validation phase of the manufacturing process for the drug and will present a complete chemistry, manufacturing and controls (CMC) update to the United States Food and Drug Administration (FDA) for their review and meet with them for further guidance later this quarter. Following the completion of this meeting, the subsequent update of the regulatory documents, and pending the necessary regulatory approvals, Bradmer will be in a position to initiate the Phase III trial early in 2008.

Bradmer's proposed Phase III trial, evaluating Neuradiab as a treatment for primary glioblastoma multiforme (GBM), is a randomized two arm multi-center study targeting 380 patients in each arm comparing the current standard of care with a group receiving Neuradiab as an adjunct to the current standard of care.

About Bradmer Pharmaceuticals Inc. (http://www.bradmerpharma.com)

Bradmer Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new and innovative cancer therapies. Bradmer's lead clinical candidate, Neuradiab, was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme. To date, over US$60 million in grants and related support has driven research and development of the licensed treatment, which has been delivered to over 200 patients with promising results and has completed Phase II clinical trials at Duke University. Bradmer is currently in the process of organizing a pivotal multi-center clinical trial of the licensed treatment. Neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency.

Bradmer Pharmaceuticals Inc.'s common shares have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties, which may include but are not limited to, the receipt of all regulatory approvals required to conduct the proposed clinical trial of Neuradiab, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.


'/>"/>
SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Bradmer announces management changes
2. Bradmer provides Phase III Neuradiab trial update and guidance
3. Bradmer to present at Rodman & Renshaw Healthcare Conference
4. MSU engineering team designs innovative medical device
5. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
7. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
8. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
9. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
10. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
11. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing skills ... patients and their families pay tribute to a genetic counselor by nominating him or ... Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome magazine ...
(Date:6/24/2016)... ... 24, 2016 , ... The Haute Beauty Network, affiliated with ... as a prominent plastic surgeon and the network’s newest partner. , Dr. ... handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands by ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, LLC ... by obtaining investment capital for emerging technology companies. SCP has delivered investment ... resulted in more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 /PRNewswire/ ... Diabetes Tomorrow,s Leaders Scholarship is any indication, the future ... today online at www.diabetesscholars.org by the Diabetes ... stand in the way of academic and community service ... scholarship program since 2012, and continues to advocate for ...
Breaking Medicine Technology: